Frequency and Clinical Impact of KRAS Mutations in Patients with Colorectal Cancer from the Middle East


  • Jamal Zekri King Faisal Specialist Hospital Research Centre, Oncology, Jeddah, Saudi Arabia
  • Syed Mustafa Karim College of Medicine, Al-Faisal University, Saudi Arabia
  • Ahmed Al-Shehri National Guard Hospital, Oncology, Jeddah, Saudi Arabia
  • Mervat Mahrous King Fahad Hospital, Oncology, Madinah, Saudi Arabia
  • Tarek Darwish King Abdulaziz Hospital and Oncology Centre, Jeddah, Saudi Arabia
  • Hani El Taani King Abdullah Medical City, Oncology, Makkah, Saudi Arabia



KRAS mutation, colorectal cancer, Middle East, EGFR Inhibitors.


  Background: Colorectal cancer (CRC) is a significant healthcare burden worldwide and in the Middle East (ME). KRAS mutation confers resistance to epidermal growth factor receptor (EGFR) inhibitors in the treatment of advanced CRC. Data regarding the rate of KRAS mutation from the ME are scattered and scarce. We aim to collect and review all sizable studies evaluating the frequency of KRAS mutations in CRC patients from the ME.

Method: A Pubmed and Google Scholar search was conducted using keywords including KRAS, K-ras, colorectal cancer and Middle East, along with names of each ME country. Studies including over 90 patients were included in the review.

Result: Eleven studies containing more than 90 patients were identified. Among all eleven studies, KRAS mutation rate ranged from 13 to 56%. Five studies reported KRAS mutation rate in M1 stage either exclusively or as part of subgroup analysis. In these studies, mutations were found in 8-45% of cases. KRAS mutations were associated with female gender, M1 stage and high CEA in 3, 2, and 1 studies respectively.

Conclusion: There is a broad range of variability in KRAS mutation rate reported in different studies from the ME. This may have been due to small number of patients in the studies and lack of centralized testing for KRAS mutations. Larger and more coordinated studies from the ME population are required to ascertain the accuracy of KRAS mutation rate.


Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians 2005; 55(2): 74-108.

Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27(22): 3677-83.

Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? British journal of cancer 2009; 100(11): 1704-19.

Slesak B, Harlozinska A, Porebska I, Bojarowski T, Lapinska J, Rzeszutko M, et al. Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis. Anticancer Res 1998; 18(4A): 2727-32.

Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19(3): 183-232.

Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351(4): 337-45.

Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England journal of medicine 2009; 360(14): 1408-17.

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2010; 28(31): 4697-705.

Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. The New England journal of medicine 1988; 319(9): 525-32.

Ibrahim EM, Zekri JM, Bin Sadiq BM. Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations. Int J Colorectal Dis 2010; 25(6): 713-21.

Soliman AS, Bondy ML, El-Badawy SA, Mokhtar N, Eissa S, Bayoumy S, et al. Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. British journal of cancer 2001; 85(7): 1037-46.

Gumus M, Dane F, Karabulut B, Uygun K, Orhan B, Aydin K, et al., editors. Interim results of observational study to determine K-ras mutation rates in patients with metastatic colorectal cancer in Turkey (TURKRAS study). European Journal of Cancer; 2013: Elsevier Sci Ltd the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, OXON, England.

Zekri J, Al-Shehri A, Mahrous M, Rizvi A, Al-Rehaily S, Darwish T, et al., editors. K-ras status in colorectal cancer tumors from 292 Saudi patients: Frequency, clinco-pathological association and clinical outcome. European Journal of Cancer; 2013: Elsevier Sci Ltd the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, OXON, England.

Abubaker J, Bavi P, Al‐Haqawi W, Sultana M, Al‐Harbi S, Al‐Sanea N, et al. Prognostic significance of alterations in KRAS isoforms KRAS‐4A/4B and KRAS mutations in colorectal carcinoma. The Journal of pathology 2009; 219(4): 435-45.

Baskin Y, Calibasi G, Amirfallah A, Dagdeviren YK, Canda AE, Sarioglu S, et al. KRAS and BRAF mutation frequencies in a series of Turkish colorectal cancer patients 2014.

Bishehsari F, Mahdavinia M, Malekzadeh R, Verginelli F, Catalano T, Sotoudeh M, et al. Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. Annals of oncology 2006; 17(suppl 7): vii91-vii6.

Selcukbiricik F, Bilici A, Tural D, Erdamar S, Soyluk O, Buyukunal E, et al. Are high initial CEA and CA 19–9 levels associated with the presence of K-ras mutation in patients with metastatic colorectal cancer? Tumor Biology 2013; 34(4): 2233-9.

Zahrani A, Kandil M, Badar T, Abdelsalam M, Al-Faiar A, Ismail A. Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia. Tumori 2013; 100(1): 75-9.

Murtaza B, Bibi A, Rashid M, Khan Y, Chaudri M, Shakoori A. Spectrum of K ras mutations in Pakistani colorectal cancer patients. Brazilian Journal of Medical and Biological Research 2014; 47(1): 35-41.

Elbjeirami WM, Sughayer MA. KRAS mutations and subtyping in colorectal cancer in Jordanian patients. Oncology letters 2012; 4(4): 705-10.

Mehdi I, Abdulmonem E, Al Bahrani BJ, editors. KRAS mutations: Does ethnicity play a role? Journal of Clinical Oncology; 2014: Amer Soc Clinical Oncology 2318 Mill Road, STE 800, Alexandria, VA 22314 USA.

Marchoudi N, Joutei HAH, Jouali F, Fekkak J, Rhaissi H. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathologie Biologie 2013; 61(6): 273-6.

Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM, et al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer 2013; 108(8): 1757-64.

Van Cutsem E, Köhne C-H, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology 2011: JCO 2010.33. 5091.

Sameer AS, Chowdhri NA, Abdullah S, Shah ZA, Siddiqi MA. Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report. Indian J Cancer 2009; 46(3): 219-25.

Chaiyapan W, Duangpakdee P, Boonpipattanapong T, Kanngern S, Sangkhathat S. Somatic mutations of K-ras and BRAF in Thai colorectal cancer and their prognostic value. Asian Pac J Cancer Prev 2013; 14(1): 329-32.

Segal G, Liebermann N, Klang S, Siegelmann-Daniel N, Beit-Or A, Klien B, et al. [Identification of K-RAS mutations in colorectal cancer patients in Israel]. Harefuah 2011; 150(5): 447-50, 91.

Al-Allawi N, Ismaeel A, Ahmed N, Merza N. The frequency and spectrum of K-ras mutations among Iraqi patients with sporadic colorectal carcinoma. Indian journal of cancer 2012; 49(1): 163.

Soliman A, Bondy M, El-Badawy S, Mokhtar N, Eissa S, Bayoumy S, et al. Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. British journal of cancer 2001; 85(7): 1037.

Aissi S, Buisine M-P, Zerimech F, Kourda N, Moussa A, Manai M, et al. KRAS mutations in colorectal cancer from Tunisia: relationships with clinicopathologic variables and data on TP53 mutations and microsatellite instability. Molecular biology reports 2013; 40(11): 6107-12.

Jadda H, editor Mutation Analysis Of Kras And Braf Hotspots In Moroccan Patients With Colorectal Cancer. Qatar Foundation Annual Research Conference; 2013.

Chan AO, Soliman AS, Zhang Q, Rashid A, Bedeir A, Houlihan PS, et al. Differing DNA methylation patterns and gene mutation frequencies in colorectal carcinomas from Middle Eastern countries. Clinical cancer research 2005; 11(23): 8281-7.

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2010: JCO 2009.27. 6055.

Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine 2008; 359(17): 1757-65.

Zalis M, Vieira F, Zalcberg-Renault I, Bonamino M, Ferreira C, Oliveira S, editors. KRAS mutation profile in colorectal cancer patients in Brazil: A cohort of 989 individuals. ASCO Annual Meeting Proceedings; 2009.

Ferreira CG, Aran V, Zalcberg-Renault I, Victorino AP, Salem JH, Bonamino MH, et al. KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients. BMC gastroenterology 2014; 14(1): 73.

Zekri J, Rizvi A, Al-Maghrabi J, bin Sadiq B. K-ras in colorectal cancer tumors from Saudi patients: frequency, clinco-pathological association and clinical outcome. The Open Colorectal Cancer Journal 2012; 5: 22-7.

Ruiz-Candelaria Y, Miranda-Diaz C, Hunter-Mellado RF. K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011. The International journal of biological markers 2013; 28(4): e393.

Webb A, Scott-Mackie P, Cunningham D, Norman A, Andreyev J, O'Brien M, et al. The prognostic value of CEA, βHCG, AFP, CA125, CA19-9 and C-erb B-2,(βHCG immunohistochemistry in advanced colorectal cancer. Annals of oncology 1995; 6(6): 581-8.

Elsamany SA, Alzahrani AS, Mohamed MM, Elmorsy SA, Zekri JE, Al-Shehri AS, et al. Clinico-pathological patterns and survival outcome of colorectal cancer in young patients: Western Saudi Arabia experience. Asian Pacific journal of cancer prevention: APJCP 2013; 15(13): 5239-43.

Liang J, Huang K, Cheng A, Jeng Y, Wu M, Wang S. Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. British journal of surgery 2003; 90(2): 205-14.

Liu L, Cao Y, Tan A, Liao C, Mo Z, Gao F. Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials. Colorectal disease: the official journal of the Association of Coloproctology of Great Britain and Ireland 2010; 12(5): 399-406.

Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncology 2014; 15(10): 1065-75.

Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncology 2014; 15(6): 569-79.

Lang I, Kohne CH, Folprecht G, Rougier P, Curran D, Hitre E, et al. Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. Eur J Cancer 2013; 49(2): 439-48.

Yamaguchi K, Ando M, Ooki A, Beier F, Guenther S, Von Hohnhorst P, et al. Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI plus cetuximab in the CRYSTAL study. Eur J Cancer 2015; 51: S370-S1.

Downward J. Targeting RAS signalling pathways in cancer therapy. Nature Reviews Cancer 2003; 3(1): 11-22.

Yoon HH, Tougeron D, Shi Q, Alberts SR, Mahoney MR, Nelson GD, et al. KRAS Codon 12 and 13 Mutations in Relation to Disease-Free Survival in BRAF–Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance). Clinical cancer research 2014; 20(11): 3033-43.

Mannan A, Hahn-Strömberg V. K‐ras mutations are correlated to lymph node metastasis and tumor stage, but not to the growth pattern of colon carcinoma. Apmis 2012; 120(6): 459-68.

Nakanishi R, Harada J, Tuul M, Zhao Y, Ando K, Saeki H, et al. Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer. International journal of clinical oncology 2013; 18(6): 1042-8.

Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. Journal of Clinical Oncology 2010; 28(3): 466-74.

Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clinical cancer research 2009; 15(23): 7322-9.

Inoue Y, Saigusa S, Iwata T, Okugawa Y, Toiyama Y, Tanaka K, et al. The prognostic value of KRAS mutations in patients with colorectal cancer. Oncology reports 2012; 28(5): 1579-84.

Andreyev H, Norman A, Cunningham D, Oates J, Dix B, Iacopetta B, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’study. British journal of cancer 2001; 85(5): 692.

Douillard J-Y, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab–FOLFOX4 treatment and RAS mutations in colorectal cancer. New England Journal of Medicine 2013; 369(11): 1023-34.




How to Cite

Jamal Zekri, Syed Mustafa Karim, Ahmed Al-Shehri, Mervat Mahrous, Tarek Darwish, & Hani El Taani. (2016). Frequency and Clinical Impact of KRAS Mutations in Patients with Colorectal Cancer from the Middle East. Journal of Analytical Oncology, 5(2),  67–74.